RT @NatRevRheumatol: Results of the FAST trial presented at #ACR20 - Safety study required by the EMA - Febuxostat non
Tweet Content
Results of the FAST trial presented at #ACR20
- Safety study required by the EMA
- Febuxostat non-inferior to allopurinol for any outcomes
- Long-term use of febuxostat is not associated with an increased risk of death
Published in @TheLancet today https://t.co/EvJGPpDCR8
Links
DEFINE_ME
https://bit.ly/3lgoGCH
Show on Archive Page
On
Display in Search Results
On